Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum

被引:49
作者
Blazevic, Anela [1 ]
Hofland, Johannes [1 ]
Hofland, Leo J. [1 ]
Feelders, Richard A. [1 ]
de Herder, Wouter W. [1 ]
机构
[1] Erasmus Univ, Med Ctr, Erasmus MC,Sect Endocrinol, ENETS Ctr Excellence,Dept Internal Med, Rotterdam, Netherlands
关键词
neuroendocrine tumour; fibrosis; growth factors; targeted therapy; tumour microenvironment; GROWTH-FACTOR RECEPTOR; CONSENSUS GUIDELINES UPDATE; METASTATIC CARCINOID-TUMOR; SUBSTANCE-P; FACTOR-ALPHA; SEROTONIN SYNTHESIS; SIGNALING PATHWAYS; TAMOXIFEN THERAPY; STELLATE CELLS; MOUSE MODEL;
D O I
10.1530/ERC-17-0380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Small intestinal neuroendocrine tumours (SI-NETs) are neoplasms characterized by their ability to secrete biogenic amines and peptides. These cause distinct clinical pathology including carcinoid syndrome, marked by diarrhoea and flushing, as well as fibrosis, notably mesenteric fibrosis. Mesenteric fibrosis often results in significant morbidity by causing intestinal obstruction, oedema and ischaemia. Although advancements have been made to alleviate symptoms of carcinoid syndrome and prolong the survival of patients with SI-NETs, therapeutic options for patients with mesenteric fibrosis are still limited. As improved insight in the complex pathogenesis of mesenteric fibrosis is key to the development of new therapies, we evaluated the literature for known and putative mediators of fibrosis in SI-NETs. In this review, we discuss the tumour microenvironment, growth factors and signalling pathways involved in the complex process of fibrosis development and tumour progression in SI-NETs, in order to elucidate potential new avenues for scientific research and therapies to improve the management of patients suffering from the complications of mesenteric fibrosis.
引用
收藏
页码:R115 / R130
页数:16
相关论文
共 108 条
[91]   Fibroblast growth factor signalling: from development to cancer [J].
Turner, Nicholas ;
Grose, Richard .
NATURE REVIEWS CANCER, 2010, 10 (02) :116-129
[92]   Brief communication: Tamoxifen therapy for nonmalignant retroperitoneal fibrosis [J].
van Bommel, EFH ;
Hendriksz, TR ;
Huiskes, AWLC ;
Zeegers, AGM .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (02) :101-106
[93]  
Vettori Serena, 2012, Open Rheumatol J, V6, P130, DOI 10.2174/1874312901206010130
[94]   PLASMA SUBSTANCE-P IN NEUROENDOCRINE TUMORS AND IDIOPATHIC FLUSHING - THE VALUE OF PENTAGASTRIN STIMULATION TESTS AND THE EFFECTS OF SOMATOSTATIN ANALOG [J].
VINIK, AI ;
GONIN, J ;
ENGLAND, BG ;
JACKSON, T ;
MCLEOD, MK ;
CHO, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (06) :1702-1709
[95]   Nerve growth factor exposure promotes tubular epithelial-mesenchymal transition via TGF-β1 signaling activation [J].
Vizza, Donatella ;
Perri, Anna ;
Toteda, Giuseppina ;
Lupinacci, Simona ;
Leone, Francesca ;
Gigliotti, Paolo ;
Lofaro, Danilo ;
La Russa, Antonella ;
Bonofiglio, Renzo .
GROWTH FACTORS, 2015, 33 (03) :169-180
[96]  
von Wichert G, 2000, CANCER RES, V60, P4573
[97]   Substance P Increases Liver Fibrosis by Differential Changes in Senescence of Cholangiocytes and Hepatic Stellate Cells [J].
Wan, Ying ;
Meng, Fanyin ;
Wu, Nan ;
Zhou, Tianhao ;
Venter, Julie ;
Francis, Heather ;
Kennedy, Lindsey ;
Glaser, Trenton ;
Bernuzzi, Francesca ;
Invernizzi, Pietro ;
Glaser, Shannon ;
Huang, Qiaobing ;
Alpini, Gianfranco .
HEPATOLOGY, 2017, 66 (02) :528-541
[98]   Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway [J].
Wang, He ;
Chen, Yili ;
Fernandez-Del Castillo, Carlos ;
Yilmaz, Omer ;
Deshpande, Vikram .
MODERN PATHOLOGY, 2013, 26 (01) :139-147
[99]   Autocrine growth inhibition by transforming growth factor β-1 (TGFβ-1) in human neuroendocrine tumour cells [J].
Wimmel, A ;
Wiedenmann, B ;
Rosewicz, S .
GUT, 2003, 52 (09) :1308-1316
[100]   Roles for Growth Factors in Cancer Progression [J].
Witsch, Esther ;
Sela, Michael ;
Yarden, Yosef .
PHYSIOLOGY, 2010, 25 (02) :85-101